Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024GlobeNewsWire • 10/16/24
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and ChemotherapyGlobeNewsWire • 10/02/24
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/05/24
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business UpdateGlobeNewsWire • 08/05/24
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024GlobeNewsWire • 07/29/24
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/03/24
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor ConferenceGlobeNewsWire • 05/16/24
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business UpdateGlobeNewsWire • 05/15/24
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024GlobeNewsWire • 05/08/24
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/01/24
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top EstimatesZacks Investment Research • 03/13/24
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business UpdateGlobeNewsWire • 03/13/24
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024GlobeNewsWire • 03/06/24
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsGlobeNewsWire • 02/28/24
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsGlobeNewsWire • 01/02/24
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023GlobeNewsWire • 11/06/23
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 11/03/23
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerGlobeNewsWire • 11/01/23